NCT02643303 2022-12-02A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible CancersLudwig Institute for Cancer ResearchPhase 1/2 Completed58 enrolled 24 charts
NCT02489448 2022-10-26Neoadjuvant MEDI4736 Concomitant With Weekly Nab-paclitaxel and Dose-dense AC for Stage I-III Triple Negative Breast CancerYale UniversityPhase 1/2 Completed68 enrolled 9 charts